Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 2, 2010, Pages 170-179

  Tamaki, Hirofumi ^a   Satoh, Hiroki ^a   Hori, Satoko ^a   Ohtani, Hisakazu ^a   Sawada, Yasufumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

ATP binding cassette transporter G2 (ABCG2); Breast cancer resistance protein (BCRP); Dietary supplement; Drug interactions; Isoflavonoids; Structure activity relationship

Indexed keywords

AGLYCONE; BREAST CANCER RESISTANCE PROTEIN; CHLORELLA EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; COUMESTROL; DAIDZEIN; DAIDZEIN 4' SULFATE; DAIDZIN; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; FORMONONETIN; GENISTIN; GLUCOSIDE DERIVATIVE; GLYCITEIN; GLYCITIN; GYMNEMA SYLVESTRE EXTRACT; HERBACEOUS AGENT; IPRIFLAVONE; ISOFLAVONE DERIVATIVE; ISOFLAVONOID; METHOTREXATE; ONONIN; PASSIFLORA INCARNATA EXTRACT; PASSION FLOWER EXTRACT; PLANT EXTRACT; PRUNETIN; RUTOSIDE; SILYBUM MARIANUM EXTRACT; SISSOTRIN; SOPHORICOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG SULFATION; HUMAN; HUMAN CELL; IC 50; MEDICINAL PLANT; MEMBRANE VESICLE; NONHUMAN; PASSIFLORA INCARNATA; PASSION FLOWER; PASSION FRUIT; PROTEIN EXPRESSION; SOYBEAN; STRUCTURE ACTIVITY RELATION;

EID: 77952652033     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.170     Document Type: Article

References (54)

1. Oostendorp, R. L., Beijnen, J. H. and Schellens, J. H. M.: The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat. Rev., 35: 137-147 (2009).
2. Lilja, J. J., Niemi, M., Fredrikson, H. and Neuvonen, P. J.: Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol., 63: 732-740 (2007).
3. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. and Ross, D. D.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 95: 15665-15670 (1998).
4. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T. and Bates, S. E.: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13 (1999).
5. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. and Dean, M.: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339 (1998).
6. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van De Vijver, M. J., Scheper, R. J. and Schellens, J. H.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 61: 3458-3464 (2001).
7. Huls, M., Brown, C. D. A., Windass, A. S., Sayer, R., van den Heuvel, J. J. M. W., Heemskerk, S., Russel, F. G. M. and Masereeuw, R.: The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int., 73: 220-225 (2008).
8. Volk, E. L., Farley, K. M., Wu, Y., Li, F., Robey, R. W. and Schneider, E.: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 62: 5035-5040 (2002).
9. Doyle, L. A. and Ross, D. D.: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 22: 7340-7358 (2003).
10. Robey, R. W., Medina-Perez, W. Y., Nishiyama, K., Lahusen, T., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D. and Bates, S. E.: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 7: 145-152 (2001).
11. Matsushima, S., Maeda, K., Kondo, C., Hirano, M., Sasaki, M., Suzuki, H. and Sugiyama, Y.: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther., 314: 1059-1067 (2005).
12. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. and Sugiyama, Y.: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 68: 800-807 (2005).
13. Breedveld, P., Zelcer, N., Pluim, D., Sonmezer, O., Tibben, M. M., Beijnen, J. H., Schinkel, A. H., van Tellingen, O., Borst, P. and Schellens, J. H. M.: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res., 64: 5804-5811 (2004).
14. Suzuki, K., Doki, K., Homma, M., Tamaki, H., Hori, S., Ohtani, H., Sawada, Y. and Kohda, Y.: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol., 67: 44-49 (2009).
15. Jonker, J. W., Smit, J. W., Brinkhuis, R. F., Maliepaard, M., Beijnen, J. H., Schellens, J. H. and Schinkel, A. H.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst., 92: 1651-1656 (2000).
16. Stewart, C. F., Leggas, M., Schuetz, J. D., Panetta, J. C., Cheshire, P. J., Peterson, J., Daw, N., Jenkins, J. J., Gilbertson, R., Germain, G. S., Harwood, F. C. and Houghton, P. J.: Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res., 64: 7491-7499 (2004).
17. Merino, G., Jonker, J. W., Wagenaar, E., van Herwaarden, A. E. and Schinkel, A. H.: The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol., 67: 1758-1764 (2005).
18. Polli, J. W., Baughman, T. M., Humphreys, J. E., Jordan, K. H., Mote, A. L., Webster, L. O., Barnaby, R. J., Vitulli, G., Bertolotti, L., Read, K. D. and Serabjit-Singh, C. J.: The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab. Dispos., 32: 722-726 (2004).
19. Zaher, H., Khan, A. A., Palandra, J., Brayman, T. G., Yu, L. and Ware, J. A.: Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol. Pharm., 3: 55-61 (2006).
20. Yamasaki, Y., Ieiri, I., Kusuhara, H., Sasaki, T., Kimura, M., Tabuchi, H., Ando, Y., Irie, S., Ware, J., Nakai, Y., Higuchi, S. and Sugiyama, Y.: Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Mol. Ther., 84: 95-103 (2008).
21. Sparreboom, A., Loos, W. J., Burger, H., Sissung, T. M., Verweij, J., Figg, W. D., Nooter, K. and Gelderblom, H.: Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther., 4: 650-658 (2005).
22. Zhang, W., Yu, B., He, Y., Fan, L., Li, Q., Liu, Z., Wang, A., Liu, Y., Tan, Z., Fen-Jiang, Huang, Y. and Zhou, H.: Role of BCRP 421C > A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta., 373: 99-103 (2006).
23. Imai, Y., Tsukahara, S., Asada, S. and Sugimoto, Y.: Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res., 64: 4346-4352 (2004).
24. Zhang, S., Yang, X. and Morris, M. E.: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 65: 1208-1216 (2004).
25. Cooray, H. C., Janvilisri, T., van Veen, H. W., Hladky, S. B. and Barrand, M. A.: Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 317: 269-275 (2004).
26. Liu, X., Tee, H. and Go, M.: Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem., 16: 171-180 (2008).
27. Yoshida, N., Takada, T., Yamamura, Y., Adachi, I., Suzuki, H. and Kawakami, J.: Inhibitory effects of terpenoids on multidrug resistance-associated protein 2-and breast cancer resistance protein-mediated transport. Drug Metab. Dispos., 36: 1206-1211 (2008).
28. Ji, Y. and Morris, M. E.: Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res., 21: 2261-2269 (2004).
29. Ahmed-Belkacem, A., Macalou, S., Borrelli, F., Capasso, R., Fattorusso, E., Taglialatela-Scafati, O. and Pietro, A. D.: Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J. Med. Chem., 50: 1933-1938 (2007).
30. Zhang, S., Yang, X., Coburn, R. A. and Morris, M. E.: Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol., 70: 627-639 (2005).
31. Ahmed-Belkacem, A., Pozza, A., Muñoz-Mart́inez, F., Bates, S. E., Castanys, S., Gamarro, F., Pietro, A. D. and Pé rez-Victoria, J. M.: Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res., 65: 4852-4860 (2005).
32. Katayama, K., Masuyama, K., Yoshioka, S., Hasegawa, H., Mitsuhashi, J. and Sugimoto, Y.: Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol., 60: 789-797 (2007).
33. Enokizono, J., Kusuhara, H. and Sugiyama, Y.: Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol., 72: 967-975 (2007).
34. Wang, X. and Morris, M. E.: Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab. Dispos., 35: 268-274 (2007).
35. Thompson, L. U., Boucher, B. A., Cotterchio, M., Kreiger, N. and Liu, Z.: Dietary phytoestrogens, including isoflavones, lignans, and coumestrol, in nonvitamin, nonmineral supplements commonly consumed by women in Canada. Nutr. Cancer, 59: 176-184 (2007).
36. Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Rompay, M. V. and Kessler, R. C.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA, 280: 1569-1575 (1998).
37. Hayashi, C.: On the prediction of phenomena from qualitative data and the quantification of qualitative data from the mathematico-statistical point of view. Ann. Inst. Statistical Math., 3: 69-98 (1952).
38. Mitomo, H., Kato, R., Ito, A., Kasamatsu, S., Ikegami, Y., Kii, I., Kudo, A., Kobatake, E., Sumino, Y. and Ishikawa, T.: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J., 373: 767-774 (2003).
39. Nozaki, Y., Kusuhara, H., Kondo, T., Iwaki, M., Shiroyanagi, Y., Nakayama, H., Horita, S., Nakazawa, H., Okano, T. and Sugiyama, Y.: Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther., 322: 1162-1170 (2007).
40. Food Safety Commission.: Fundamental concepts in the safety assessment of foods containing soy isoflavones for the purpose of specified health use. http://www.fsc.go.jp/english/evaluationreports/newfoods_sphealth/soy_isoflavones.pdf (accessed 08/03/09).
41. AFSSA.: Presentation du rapport sur "Securite et benefices des phyto-estrogenes apportes l'alimentation-recommandations. (2005).
42. Italian Government.: Gazzetta Ufficiale della Repubblica Italiana 18/7/2002, number 188, annex 2 (2002).
43. Zhang, L., Zhang, Y. D., Strong, J. M., Reynolds, K. S. and Huang, S.-M.: A regulatory viewpoint on transporter-based drug interactions. Xenobiotica, 38: 709-724 (2008).
44. Klejdus, B., Mikelová, R., Petrlová, J., Potesil, D., Adam, V., Stiborova, M., Hodek, P., Vacek, J., Kizek, R. and Kuban, V.: Evaluation of isoflavone aglycon and glycoside distribution in soy plants and soybeans by fast column high-performance liquid chromatography coupled with a diode-array detector. J. Agric. Food Chem., 53: 5848-5852 (2005).
45. Wang, H. J. and Murphy, P. A.: Mass balance study of isoflavones during soybean processing. J. Agric. Food Chem., 44: 2377-2383 (1996).
46. Medina, J. H., Paladini, A. C., Wolfman, C., de Stein, M. L., Calvo, D., Diaz, L. E. and Pena, C.: Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem. Pharmacol., 40: 2227-2231 (1990).
47. Grundmann, O., Wang, J., McGregor, G. P. and Butterweck, V.: Anxiolytic activity of a phytochemically characterized Passiflora incarnata extract is mediated via the GABAergic system. Planta Med., 74: 1769-1773 (2008).
48. Xia, C. Q., Liu, N., Miwa, G. T. and Gan, L. S.: Interactions of cyclosporin A with breast cancer resistance protein. Drug Metab. Dispos., 35: 576-582 (2007).
49. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., Tanabe, S. and Kohno, S.: Transport of 7-ethyl-10-hydroxycam-ptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832 (2001).
50. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Nezasa, K., Tallman, M. N. and Brouwer, K. L. R.: Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 27: 447-486 (2006).
51. Suzuki, M., Suzuki, H., Sugimoto, Y. and Sugiyama, Y.: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem., 278: 22644-22649 (2003).
52. Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T. and Sugimoto, Y.: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol. Pharmacol., 64: 610-618 (2003).
53. Kano, M., Takayanagi, T., Harada, K. Sawada, S. and Ishikawa, F.: Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J. Nutr., 136: 2291-2296 (2006).
54. Csanady, G. A., Oberste-Frielinghaus, H. R., Semder, B., Baur, C., Schneider, K. T. and Filser, J. G.: Distribution and unspecific protein binding of the xenoestrogens bisphenol A and daidzein. Arch. Toxicol., 76: 299-305 (2002).